Distinguished in Multiple Myeloma

Dr. Mark J. Roschewski

Hematology
6900 Georgia Ave Nw, Walter Reed Army Med Center, 
Washington, DC 
Clinical Trials:Currently Recruiting for 3 Trials
Distinguished in Multiple Myeloma
6900 Georgia Ave Nw, Walter Reed Army Med Center, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Roschewski is a Hematologist in Washington, Washington, D.c.. Dr. Roschewski is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are B-Cell Lymphoma, Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Vitrectomy.

His clinical research consists of co-authoring 124 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 19 articles and participated in 5 clinical trials in the study of Multiple Myeloma.

Specialties
Hematology
Licenses
Internal Medicine in AK
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

6900 Georgia Ave Nw, Walter Reed Army Med Center, Washington, DC 20307

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Prospective Study of Clonal Evolution in Follicular Lymphoma
Prospective Study of Clonal Evolution in Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Enrollment Status: Recruiting
Publish Date: December 08, 2025
Intervention Type: Biological
Study Drug: Nivolumab
Study Phase: Phase 2
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2025
Intervention Type: Drug
Study Drugs: TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole
Study Phase: Phase 2
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug, Biological
Study Drugs: Dexamethasone, Carfilzomib, Daratumumab
Study Phase: Phase 2
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Study Phase: Phase 1
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Biological, Diagnostic test, Drug, Procedure
Study Drugs: IFN-Alpha, Rituximab, EPOCH
Study Phase: Phase 2
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Rituximab, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study
Enrollment Status: Completed
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Carfilzomib, Revlimid, Dexamethasone
Study Phase: Phase 2
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
Enrollment Status: Completed
Publish Date: March 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
Enrollment Status: Terminated
Publish Date: February 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

124 Total Publications

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025
Similar Doctors
Elite in Multiple Myeloma
Dr. Djordje Atanackovic
Hematology | Hematology Oncology
Elite in Multiple Myeloma
Dr. Djordje Atanackovic
Hematology | Hematology Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (30.5 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances

Djordje Atanackovic is a Hematologist and a Hematologist Oncology provider in Baltimore, Maryland. Dr. Atanackovic is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Multiple Myeloma
Dr. Aaron P. Rapoport
Hematology
Elite in Multiple Myeloma
Dr. Aaron P. Rapoport
Hematology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (30.5 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aaron Rapoport is a Hematologist in Baltimore, Maryland. Dr. Rapoport is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is currently accepting new patients.

Elite in Multiple Myeloma
Dr. Mehmet H. Kocoglu
Hematology Oncology | Hematology | Oncology
Elite in Multiple Myeloma
Dr. Mehmet H. Kocoglu
Hematology Oncology | Hematology | Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (30.5 miles away)
410-328-1230
Languages Spoken:
English, German, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mehmet Kocoglu is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Kocoglu is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kocoglu is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Roschewski's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile